RootsAnalysis hasannounced the addition of “NuclearMedicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report to its list ofofferings.
To order this 320+page report, which features 45+ figures and 100+ tables, please visit this link
Key Market Insights
§ Close to 130 industry and non-industry players, across the globe, claimto have the necessary expertise and supporting infrastructure to manufacture awide variety of radioisotopes, for in-house use, or as a contract service
§ The market isfragmented, featuring the presence of companies in both developed anddeveloping nations, which are capable of manufacturing radiopharmaceuticals forvarious applications at different scales of production
§ The growing interestin this field is reflected in the yearly growth in partnership activity; themajority of deals inked in the recent past include manufacturing and supplyagreements for various types of radiopharmaceuticals
§ Stakeholders are actively expanding their capabilities in order toenhance their respective nuclear medicine and radiopharmaceutical manufacturingcapabilities and, thereby, maintain a competitive edge in this industry
§ Case Study: The decay product of Mo-99, Tc-99m,is used in majority of the radioactivity-based diagnostic applications in theUS; reactors in the European region alone contribute to 60% of the globalproduction capacity
§ In the long-term, the forecasted opportunity is anticipated to be higherfor radioisotopes intended for diagnostic applications, mostly for use in thefield of cardiology, with North America holding the dominant position
§ SPECT and beta-emitters are anticipated to generate the majority shareof revenues across diagnostic and therapeutic applications, respectively, forboth in-house use and radiopharmaceutical supply contracts
For more information, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Nuclear Medicines and Radiopharmaceuticals
3.3. Historical Evolution of Radiopharmaceuticals
3.4. Applications of Radiopharmaceuticals
3.4.1. Nuclear Imaging / Diagnosis
3.4.1.1. Single Photon Emission Computed Tomography
3.4.1.2. Positron Emission Tomography
3.4.2. Therapeutic Use
3.5. Production of Radiopharmaceuticals
3.5.1. Radionuclide Generator
3.5.2. Particle Accelerator (Cyclotron)
3.5.3. Nuclear Reactor
3.6. Regulatory Framework forRadiopharmaceuticals
3.6.1. Guidelines for the Production ofRadiopharmaceuticals
3.6.2. Guidelines for Labelling andPackaging of Radiopharmaceuticals
3.6.3. Guidelines for Storage ofRadiopharmaceuticals
3.7. Need for Outsourcing RadiopharmaceuticalsManufacturing
3.8. Selecting a CMO Partner forRadiopharmaceuticals Manufacturing
3.9. Current Scenario and FutureProspects Related to Radiopharmaceuticals
4. NUCLEAR MEDICINE ANDRADIOPHARMACEUTICALS MANUFACTURERS (INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nuclear Medicine andRadiopharmaceuticals Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose ofProduction
4.2.4. Analysis by GeographicalLocation of Headquarters
4.2.5. Analysis by GeographicalLocation of Manufacturing Facilities
4.2.6. Analysis by Scale of Production
4.2.7. Analysis by Application Area
4.2.8. Analysis by Type of Radioisotope
4.2.8.1. Radioisotopes for Diagnostic Use
4.2.8.2. Radioisotopes for Therapeutic Use
4.2.9 Analysis by Target Therapeutic Area
4.2.10 Analysis by Service(s) Offered
